Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PARP inhibitors: a treatment option for AML?

A new study provides a rationale for the use of poly (ADP-ribose) polymerase (PARP) inhibitors to trigger irreparable DNA damage as a therapeutic approach in acute myeloid leukemia (AML). It also provides support for combining PARP inhibitors with agents that reduce HOXA9 protein levels.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The effect of poly (ADP-ribose) polymerase (PARP) inhibition on acute leukemia driven by the oncogenic transcription factors AML1-ETO, PML-RARα and MLL-AF9, as well as the underlying mechanism of sensitivity to PARPi.


  1. Lo-Coco, F. et al. N. Engl. J. Med. 369, 111–121 (2013).

    Article  CAS  Google Scholar 

  2. Ley, T.J. et al. Nature 456, 66–72 (2008).

    Article  CAS  Google Scholar 

  3. Esposito, M.T., Zhao, L. & So, C.W. Nat. Med. 21, 1481–1490 (2015).

    Article  CAS  Google Scholar 

  4. Mateo, J. et al. N. Engl. J. Med. 373, 1697–1708 (2015).

    Article  CAS  Google Scholar 

  5. Santos, M.A. et al. Nature 514, 107–111 (2014).

    Article  CAS  Google Scholar 

  6. Faber, J. et al. Blood 113, 2375–2385 (2009).

    Article  CAS  Google Scholar 

  7. Yang, C. et al. Cancer Res. 75, 1838–1845 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Stephen D Nimer.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, L., Hamard, PJ. & Nimer, S. PARP inhibitors: a treatment option for AML?. Nat Med 21, 1393–1394 (2015).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer